Advertisement

Cancer risk in patients with Parkinson’s disease in South Korea: A nationwide, population-based cohort study

  • Joo-Hyun Park
    Affiliations
    Department of Family Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Republic of Korea
    Search for articles by this author
  • Author Footnotes
    1 These two co-corresponding authors contributed to this study equally.
    Do-Hoon Kim
    Correspondence
    Corresponding author: Department of Family Medicine, Korea University Ansan Hospital, Korea University College of Medicine, 123, Jeokgeum-ro, Danwon-gu, Ansan-si, Gyeonggi-do, 15355, Republic of Korea. Fax: +82-10-8636-6567.
    Footnotes
    1 These two co-corresponding authors contributed to this study equally.
    Affiliations
    Department of Family Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Republic of Korea
    Search for articles by this author
  • Author Footnotes
    1 These two co-corresponding authors contributed to this study equally.
    Yong-Gyu Park
    Correspondence
    Corresponding author: Department of Biostatistics, College of Medicine, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul, 06591, Republic of Korea.
    Footnotes
    1 These two co-corresponding authors contributed to this study equally.
    Affiliations
    Department of Biostatistics, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
    Search for articles by this author
  • Do-Young Kwon
    Affiliations
    Department of Neurology, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Republic of Korea
    Search for articles by this author
  • Moonyoung Choi
    Affiliations
    Department of Family Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Republic of Korea
    Search for articles by this author
  • Jin-Hyung Jung
    Affiliations
    Department of Biostatistics, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
    Search for articles by this author
  • Kyungdo Han
    Affiliations
    Department of Biostatistics, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
    Search for articles by this author
  • Author Footnotes
    1 These two co-corresponding authors contributed to this study equally.

      Highlights

      • Patients with Parkinson’s disease (PD) had a lower overall cancer risk than those without PD.
      • Patients with PD showed lower risk of colorectal cancer, gastric cancer, liver cancer, and pancreatic cancer.
      • They also showed lower risk of lung cancer, prostate cancer, laryngeal cancer, leukaemia and uterine cervical cancer.
      • Despite environmental, ethnic and socioeconomic differences, our results were consistent with previous Western studies.
      • Further studies are required to investigate the underlying mechanism of the association between PD and cancer.

      Abstract

      Introduction

      The association between Parkinson’s disease (PD) and cancer development is controversial, especially in Asia. Therefore, we conducted a nationwide population-based cohort study to assess the overall cancer risk and risk for specific cancers in patients with PD in Korea.

      Methods

      Using data from the Korean National Health Insurance Database, we analysed 52,009 patients diagnosed with PD between 2010 and 2015 and 260,045 individuals without PD. Patients previously diagnosed with cancer were excluded. The age- and sex-matched cohorts were followed up until 2016 for cancer development. Cox proportional hazards regression models were used to evaluate the relationship between PD and cancer.

      Results

      Patients with PD had a lower overall cancer risk (hazard ratio [HR], 0.78; 95% confidence interval [CI], 0.74–0.82) after adjustment for multiple covariates during 2,022,852.6 person-years of follow-up. Patients with PD showed significantly lower risk of laryngeal cancer (HR, 0.45; 95% CI, 0.21–0.84), gastric cancer (HR, 0.72; 95% CI, 0.63–0.82), colorectal cancer (HR, 0.675; 95% CI, 0.60–0.76), liver cancer (HR, 0.80; 95% CI, 0.67–0.95), pancreatic cancer (HR, 0.75; 95% CI, 0.62–0.91), lung cancer (HR, 0.73; 95% CI, 0.63–0.84), leukaemia (HR, 0.49; 95% CI, 0.24–0.89), uterine cervical cancer (HR, 0.64; 95% CI, 0.40–0.99) and prostate cancer (HR, 0.78; 95% CI, 0.66–0.91).

      Conclusion

      This nationwide population-based cohort study revealed that patients with PD had lower overall cancer risk and lower risk of specific cancers. Contrary to the results of the recent Asian study, this large cohort study revealed that patients with PD were less likely to develop cancer than those without PD in Korea. Our results were consistent with those of previous Western studies, despite differences in ethnicity and environment.

      Keywords

      Abbreviations:

      CI (confidence interval), DM (diabetes mellitus), HR (hazard ratio), ICD-10-CM (International Classification of Diseases), 10th Revision (Clinical Modification), NHIS (National Health Insurance Service), PD (Parkinson’s disease), RIDs (rare intractable diseases)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • de Lau L.M.
        • Breteler M.M.
        Epidemiology of Parkinson's disease.
        Lancet Neurol. 2006; 5: 525-535
        • Kalia L.V.
        • Lang A.E.
        Parkinson's disease.
        Lancet. 2015; 386: 896-912
        • Macerollo A.
        • Chen J.C.
        Trends in the incidence of Parkinson disease.
        JAMA Neurol. 2016; 73: 1497-1498
        • Ong E.L.
        • Goldacre R.
        • Goldacre M.
        Differential risks of cancer types in people with Parkinson's disease: a national record-linkage study.
        Eur J Cancer. 2014; 50: 2456-2462
        • Catala-Lopez F.
        • Suarez-Pinilla M.
        • Suarez-Pinilla P.
        • Valderas J.M.
        • Gomez-Beneyto M.
        • Martinez S.
        • et al.
        Inverse and direct cancer comorbidity in people with central nervous system disorders: a meta-analysis of cancer incidence in 577,013 participants of 50 observational studies.
        Psychother Psychosom. 2014; 83: 89-105
        • Bajaj A.
        • Driver J.A.
        • Schernhammer E.S.
        Parkinson's disease and cancer risk: a systematic review and meta-analysis.
        Cancer Causes Control. 2010; 21: 697-707
        • Lin P.Y.
        • Chang S.N.
        • Hsiao T.H.
        • Huang B.T.
        • Lin C.H.
        • Yang P.C.
        Association between Parkinson disease and risk of cancer in Taiwan.
        JAMA Oncol. 2015; 1: 633-640
        • Driver J.A.
        • Logroscino G.
        • Buring J.E.
        • Gaziano J.M.
        • Kurth T.
        A prospective cohort study of cancer incidence following the diagnosis of Parkinson's disease.
        Cancer Epidemiol Biomark Prev. 2007; 16: 1260-1265
        • Olsen J.H.
        • Friis S.
        • Frederiksen K.
        • McLaughlin J.K.
        • Mellemkjaer L.
        • Moller H.
        Atypical cancer pattern in patients with Parkinson's disease.
        Br J Canc. 2005; 92: 201-205
      1. World Health Organization (WHO) CANCER FACT SHEETS. https://www.who.int/en/news-room/fact-sheets/detail/cancer [accessed 2019]..

        • Garber K.
        Parkinson's disease and cancer: the unexplored connection.
        J Natl Cancer Inst. 2010; 102: 371-374
        • West A.B.
        • Dawson V.L.
        • Dawson T.M.
        To die or grow: Parkinson's disease and cancer.
        Trends Neurosci. 2005; 28: 348-352
        • Freedman D.M.
        • Wu J.
        • Chen H.
        • Engels E.A.
        • Enewold L.R.
        • Freedman N.D.
        • et al.
        Associations between cancer and Parkinson's disease in U.S. elderly adults.
        Int J Epidemiol. 2016; 45: 741-751
      2. Cancer incident cases and incidence rates, Statistics Korea. http://kostat.go.kr/[accessed 2019].

        • Tacik P.
        • Curry S.
        • Fujioka S.
        • Strongosky A.
        • Uitti R.J.
        • van Gerpen J.A.
        • et al.
        Cancer in Parkinson's disease.
        Park Relat Disord. 2016; 31: 28-33
        • Dickson D.W.
        • Braak H.
        • Duda J.E.
        • Duyckaerts C.
        • Gasser T.
        • Halliday G.M.
        • et al.
        Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria.
        Lancet Neurol. 2009; 8: 1150-1157
        • Hughes A.J.
        • Daniel S.E.
        • Kilford L.
        • Lees A.J.
        Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.
        J Neurol Neurosurg Psychiatry. 1992; 55: 181-184
        • Peretz C.
        • Gurel R.
        • Rozani V.
        • Gurevich T.
        • El-Ad B.
        • Tsamir J.
        • et al.
        Cancer incidence among Parkinson's disease patients in a 10-yrs time-window around disease onset: a large-scale cohort study.
        Park Relat Disord. 2016; 28: 68-72
        • Lomas A.
        • Leonardi-Bee J.
        • Bath-Hextall F.
        A systematic review of worldwide incidence of nonmelanoma skin cancer.
        Br J Dermatol. 2012; 166: 1069-1080
        • Erdmann F.
        • Lortet-Tieulent J.
        • Schuz J.
        • Zeeb H.
        • Greinert R.
        • Breitbart E.W.
        • et al.
        International trends in the incidence of malignant melanoma 1953-2008--are recent generations at higher or lower risk?.
        Int J Cancer. 2013; 132: 385-400
        • Sng J.
        • Koh D.
        • Siong W.C.
        • Choo T.B.
        Skin cancer trends among Asians living in Singapore from 1968 to 2006.
        J Am Acad Dermatol. 2009; 61: 426-432
        • Bellew S.
        • Del Rosso J.Q.
        • Kim G.K.
        Skin cancer in asians: part 2: melanoma.
        J Clin Aesthet Dermatol. 2009; 2: 34-36
        • Tacik P.
        • Curry S.
        • Fujioka S.
        • Strongosky A.
        • Uitti R.J.
        • van Gerpen J.A.
        • et al.
        Cancer in Parkinson's disease.
        Park Relat Disord. 2016; 31: 28-33
        • Lo R.Y.
        • Tanner C.M.
        • Van Den Eeden S.K.
        • Albers K.B.
        • Leimpeter A.D.
        • Nelson L.M.
        Comorbid cancer in Parkinson's disease.
        Mov Disord. 2010; 25: 1809-1817
        • Liu R.
        • Gao X.
        • Lu Y.
        • Chen H.
        Meta-analysis of the relationship between Parkinson disease and melanoma.
        Neurology. 2011; 76: 2002-2009
        • Hernan M.A.
        • Takkouche B.
        • Caamano-Isorna F.
        • Gestal-Otero J.J.
        A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease.
        Ann Neurol. 2002; 52: 276-284
        • Doll R.
        • Peto R.
        Mortality in relation to smoking: 20 years' observations on male British doctors.
        Br Med J. 1976; 2: 1525-1536
        • Allam M.F.
        • Campbell M.J.
        • Del Castillo A.S.
        • Fernandez-Crehuet Navajas R.
        Parkinson's disease protects against smoking?.
        Behav Neurol. 2004; 15: 65-71
        • Wirdefeldt K.
        • Weibull C.E.
        • Chen H.
        • Kamel F.
        • Lundholm C.
        • Fang F.
        • et al.
        Parkinson's disease and cancer: a register-based family study.
        Am J Epidemiol. 2014; 179: 85-94
        • Islami F.
        • Goding Sauer A.
        • Miller K.D.
        • Siegel R.L.
        • Fedewa S.A.
        • Jacobs E.J.
        • et al.
        Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States.
        CA A Cancer J Clin. 2018; 68: 31-54
      3. Korea Health Statistics 2017: Korea National Health and Nutrition Examination Survey (KNHANES Ⅶ-2), Korea Centers for Disease Control and Prevention. https://knhanes.cdc.go.kr/[accessed 2019].

        • Braak H.
        • Del Tredici K.
        • Bratzke H.
        • Hamm-Clement J.
        • Sandmann-Keil D.
        • Rub U.
        Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages).
        J Neurol. 2002; 249: III/1-III/5
        • Wakabayashi K.
        • Takahashi H.
        • Ohama E.
        • Takeda S.
        • Ikuta F.
        Lewy bodies in the visceral autonomic nervous system in Parkinson's disease.
        Adv Neurol. 1993; 60: 609-612
        • Braak H.
        • de Vos R.A.
        • Bohl J.
        • Del Tredici K.
        Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology.
        Neurosci Lett. 2006; 396: 67-72
        • Musicco M.
        • Adorni F.
        • Di Santo S.
        • Prinelli F.
        • Pettenati C.
        • Caltagirone C.
        • et al.
        Inverse occurrence of cancer and Alzheimer disease: a population-based incidence study.
        Neurology. 2013; 81: 322-328
        • Feng D.D.
        • Cai W.
        • Chen X.
        The associations between Parkinson's disease and cancer: the plot thickens.
        Transl Neurodegener. 2015; 4: 20
        • Wahabi K.
        • Perwez A.
        • Rizvi M.A.
        Parkin in Parkinson's disease and cancer: a double-edged sword.
        Mol Neurobiol. 2018; 55: 6788-6800
        • Veeriah S.
        • Taylor B.S.
        • Meng S.
        • Fang F.
        • Yilmaz E.
        • Vivanco I.
        • et al.
        Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies.
        Nat Genet. 2010; 42: 77-82
        • Strongosky A.J.
        • Farrer M.
        • Wszolek Z.K.
        Are Parkinson disease patients protected from some but not all cancers?.
        Neurology. 2008; 71 (author reply -1): 1650
        • Wszolek Z.K.
        • Pfeiffer B.
        • Fulgham J.R.
        • Parisi J.E.
        • Thompson B.M.
        • Uitti R.J.
        • et al.
        Western Nebraska family (family D) with autosomal dominant parkinsonism.
        Neurology. 1995; 45: 502-505
        • Staropoli J.F.
        Tumorigenesis and neurodegeneration: two sides of the same coin?.
        Bioessays. 2008; 30: 719-727
        • McNaught K.S.
        • Perl D.P.
        • Brownell A.L.
        • Olanow C.W.
        Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease.
        Ann Neurol. 2004; 56: 149-162
        • Montagut C.
        • Rovira A.
        • Albanell J.
        The proteasome: a novel target for anticancer therapy.
        Clin Transl Oncol. 2006; 8: 313-317
        • Schernhammer E.
        • Chen H.
        • Ritz B.
        Circulating melatonin levels: possible link between Parkinson's disease and cancer risk?.
        Cancer Causes Control. 2006; 17: 577-582
        • Wang Y.
        • Wang P.
        • Zheng X.
        • Du X.
        Therapeutic strategies of melatonin in cancer patients: a systematic review and meta-analysis.
        OncoTargets Ther. 2018; 11: 7895-7908